Pluvicto

Pluvicto (Lutetium (177Lu) Vipivotide Tetraxetan) is an advanced targeted radioligand therapy designed for the treatment of metastatic castration resistant prostate cancer (mCRPC) in patients who express prostate specific membrane antigen (PSMA). This innovative therapy combines a radioactive isotope, Lutetium 177, with a molecule that specifically binds to PSMA, a protein commonly overexpressed on prostate cancer cells. By targeting PSMA, Pluvicto delivers precise radiation directly to cancer cells while sparing surrounding healthy tissues, which enhances treatment efficacy and reduces systemic side effects.
Clinical studies have demonstrated that Pluvicto can significantly reduce tumor burden and improve progression free survival in patients with advanced prostate cancer. The therapy is administered intravenously, typically in cycles, under the supervision of specialized nuclear medicine or oncology teams. Before treatment, patients undergo imaging tests to confirm PSMA expression, ensuring that the therapy is suitable and likely to be effective.
Pluvicto represents a shift in cancer treatment toward precision medicine, offering a personalized approach that leverages the molecular characteristics of the tumor. Side effects may include mild to moderate fatigue, nausea, dry mouth, or decreased blood counts, which are generally manageable with medical support.
Manufactured under strict quality standards, Pluvicto provides a reliable option for patients with limited alternatives in advanced stages of prostate cancer. Its targeted mechanism, proven clinical benefits, and ability to enhance patient outcomes make it a key innovation in modern oncology, providing hope for patients seeking effective therapies for PSMA positive mCRPC.